Ophthalmological procedures

• US 4,328,803 A
• Filed: 10/20/1980
• Issued: 05/11/1982
• Est. Priority Date: 10/20/1980
• Status: Expired due to Term

• Current Assignee: Opthalmic Systems Incorporated
• Original Assignee: Opthalmic Systems Incorporated
• Inventors: Pape, Lawrence G.
• Primary Examiner(s): Michell, Robert W.
• Assistant Examiner(s): Swisher, Nancy A. B.
• Application Number:
  US06/198,290
• Time in Patent Office: 568 Days
• Field of Search: 128/276
• US Class Current: 604/28
• CPC Class Codes: A61F 2/14 Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
• CPC Class Codes: A61F 9/00 Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand caps with means for protecting the eyes A42B1/018; visors for helmets A42B3/22; retractors A61B17/02; manipulators specially adapted for use in surgery A61B34/70; appliances to aid invalids to move about A61H3/00; exercisers for the eyes A61H5/00; eye baths A61H35/02; sunglasses or goggles having the same features as spectacles G02C
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 31/042 Polysaccharides
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Abstract

This disclosure is directed to improved opthalmological surgical procedures on the human eyeball characterized by initially utilizing ultra-pure hyaluronic acid in the form of a solution containing the sodium salt thereof, in a sufficient concentration thereof to protect delicate eye tissue and cells, e.g., 0.5 to 1.0 wt. % and higher, and thereafter, significantly diluting the concentration thereof in the aqueous media (natural and/or synthetic) within the anterior segment of the eye viz, in situ, so as to arrive at a concentration of said sodium salt of hyaluronic acid of less than 0.5 wt. % and more usually from about 0.1 to about 0.3 wt. % prior to closure. Hence a significant dilution from the initial higher concentrations by a factor of at least about 2:1 and more usually from about 3:1 to about 10:1 is effected. Hence the concentration of said sodium hyaluronate in the natural and/or synthetic aqueous media left within the eyeball at the surgical site after closure of the procedure ranges from about 0.1 to about 0.3 wt. % in the anterior chamber.

Claims

1. In a method for protecting delicate human eye structures during ophthalmological surgical procedures by introducing into the anterior segment thereof a given volume of highly viscous physiologically buffered solution containing a sufficient concentration of sodium hyaluronate to protect delicate eye tissue, cells and structures, the improvement comprising diluting said volume in site thereby reducing the concentration thereof prior to closure such that abnormally high post-operative intra-ocular pressure within the human eye is avoided.

2. A method as in claim 1 wherein the gross concentration of said highly viscous sodium hyaluronate solution within the anterior segment at closure ranges from about 0.1 to about 0.3 wt. %.

3. A method as in claim 1 wherein the concentration of said highly viscous sodium hyaluronate solution as introduced into said anterior segment ranges from about 0.5 to about 1.0 wt. % and higher.

4. A method as in claim 1 wherein said dilution is effected endogenously.

5. A method as in claim 1 wherein said dilution is effected exogenously.

6. A method as in claim 5 wherein said exogenous dilution is conducted by directing a physiologically buffered aqueous saline solution in the region of said previously introduced highly viscous sodium hyaluronate solution.

7. A method according to claim 1 wherein said dilution is by a factor of at least 2:

1.

8. A process according to claim 1 wherein said dilution is by a factor ranging from about 3:

1 to 10;

1.

9. A method as in claim 1 wherein said surgical procedure is performed within the anterior chamber of the eye.

10. A method as in claim 1 wherein said surgical procedure involves an intra-ocular implant of a lens within the eye.

11. A method according to claim 10 wherein said implantation is effected by iris fixation.

12. A method according to claim 10 wherein said lens implantation is conducted by anterior chamber angle fixation.

13. A method according to claim 10 wherein said lens implantation is conducted by posterior chamber fixation.

14. A method as in claim 1 wherein said surgical procedure involves a corneal transplant within the eye.

15. A method as in claim 1 wherein said surgical procedure involves a cataract extraction from the eye.

16. A method as in claim 15 wherein said cataract extraction involves an intra-capsular extraction.

17. A method according to claim 15 wherein cataract extraction is obtained by extra-capsular extraction.

18. A method according to claim 15 wherein said cataract extraction is effected by phacoemulsification.

19. A method according to claim 15 wherein said cataract is removed by intra-capsular cataract extraction.

20. A method according to claim 15 wherein said cataract is removed by extra-capsular cataract extraction.

21. A method according to claim 15 wherein said cataract is removed by phacoemulsification.